Ralph Laufer
Merck & Co.
90 Papers
1.2K Citations
Ralph Laufer is an academic researcher from Merck & Co.. The author has contributed to research in topics: Ciliary neurotrophic factor & Hepatitis C virus. The author has an hindex of 33, co-authored 84 publications. Previous affiliations of Ralph Laufer include United States Military Academy & Hebrew University of Jerusalem.
Chat about Author
Papers
Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
Vincenzo Summa,Alessia Petrocchi,Fabio Bonelli,Benedetta Crescenzi,Monica Donghi,Marco Ferrara,Fabrizio Fiore,Cristina Gardelli,Odalys Gonzalez Paz,Daria J. Hazuda,Philip Jones,Olaf Kinzel,Ralph Laufer,Edith Monteagudo,Ester Muraglia,Emanuela Nizi,Federica Orvieto,Paola Pace,Giovanna Pescatore,Rita Scarpelli,Kara A. Stillmock,Marc V. Witmer,Michael Rowley +22 more
TL;DR: The discovery of Raltegravir is reported, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection, which derives from the evolution of 5,6-dihydroxypyrimidine-4-carboxamides and N-methyl- 4-hydroxypyridinone-car boxamides, which exhibited potent inhibition of the HIV-Integrase catalyzed strand transfer process.
669
Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation.
Gabriella Rizzuto,Manuela Cappelletti,Domenico Maione,Rocco Savino,Domenico Lazzaro,Patrizia Costa,Iacob Mathiesen,Riccardo Cortese,Gennaro Ciliberto,Ralph Laufer,Nicola La Monica,Elena Fattori +11 more
TL;DR: It is shown that an electric treatment in the form of high-frequency, low-voltage electric pulses can increase more than 100-fold the production and secretion of a recombinant protein from mouse skeletal muscle and provides a potentially safe and low-cost treatment for serum protein deficiencies.
351
Enhancing B- and T-Cell Immune Response to a Hepatitis C Virus E2 DNA Vaccine by Intramuscular Electrical Gene Transfer
Silvia Zucchelli,Stefania Capone,Elena Fattori,Antonella Folgori,Annalise Di Marco,Danilo R. Casimiro,Adam J. Simon,Ralph Laufer,Nicola La Monica,Riccardo Cortese,Alfredo Nicosia +10 more
TL;DR: An improved genetic immunization strategy for eliciting a full spectrum of anti-hepatitis C virus (HCV) envelope 2 (E2) glycoprotein responses in mammals through electrical gene transfer (EGT) of plasmid DNA into muscle fibers potentially provides a safe, low-cost treatment that may be scaled up to humans.
134
Behavioural effects of receptor-specific substance P agonists.
Dalia Papir-Kricheli,Joseph Frey,Ralph Laufer,Chaim Gilon,Michael Chorev,Zvi Selinger,Marshall Devor +6 more
TL;DR: Septide and senktide are synthetic substance P (SP) agonists with extremely high selectivity for 1 of the 3 known SP receptor subtypes and when injected intrathecally, they produced dramatically different behavioural effects.
133
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
Joel Kaye,Victor Piryatinsky,Tal Birnberg,Tal Hingaly,Emanuel Raymond,Rina Kashi,Einat Amit-Romach,Ignacio S. Caballero,Fadi Towfic,Mark A. Ator,Efrat Rubinstein,Daphna Laifenfeld,Aric Orbach,Doron Shinar,Yael Marantz,Iris Grossman,Volker Knappertz,Michael R. Hayden,Ralph Laufer +18 more
TL;DR: The consequences of AhR activation in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) using AhR knockout mice are tested and it is demonstrated that the pronounced effect of laquinimod on clinical score, CNS inflammation, and demyelination in EAE was abolished in AhR−/− mice.
122